文献速递前列腺癌

PROCLAIM试验患者报告结局:前列腺癌胚系基因检测的影响

Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-09-22

基于PROCLAIM试验的二次分析,评估494例前列腺癌患者对胚系基因检测结果的回忆、理解、临床建议采纳及心理影响。60%和71%的患者能准确回忆和解读结果,阳性结果患者对临床建议采纳率高,但VUS结果解读不一致,部分患者采取未推荐的管理策略,总体心理危害小。

要点

  • 60%和71%的患者能准确回忆和解读胚系基因检测结果。
  • 阳性结果患者中93%完成或计划完成至少一项临床建议。
  • VUS和阴性结果患者中分别有57%和部分采取未推荐的管理策略。

核心结论

  • 前列腺癌患者胚系基因检测未造成明显的心理伤害。
  • 阳性结果患者对临床医生推荐的管理策略采纳率高。
  • VUS结果的解读存在不一致,部分医生和患者采取不恰当的管理策略,需要加强沟通教育。

研究设计与样本

  • PROCLAIM试验的二次分析,纳入494例有信息性调查回复的前列腺癌患者。
  • 患者报告结局按胚系基因检测结果整体分析,组间差异采用双侧Fisher精确检验,显著性设定为p<0.05。

主要发现

  • 494例患者中,60%能准确回忆胚系基因检测结果,71%能准确解读结果;阴性结果患者准确率最高,仅VUS结果患者最低。
  • 42/55(76%)阳性结果患者临床医生基于检测结果提出建议,其中39例(93%)完成或计划完成超过1项临床建议。
  • VUS和阴性结果患者中,分别有160/221(72%)和211/218(97%)未获得进一步临床建议;但57%(213/371)的这些患者表示自己或家属打算采取临床医生未推荐的管理策略。
  • 超过90%的受访患者报告检测后对自身或家属的担忧程度未增加。

临床怎么用

  • 临床医生应向患者充分解释胚系基因检测结果,特别是VUS结果的不确定性,避免患者采取未经验证的管理策略。
  • 对于阳性结果患者,应依据检测结果制定并沟通临床管理建议,以提高采纳率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although germline genetic testing can inform medical management for patients with prostate cancer (PCa), data are limited regarding patient-reported outcomes (PROs) after germline genetic testing for PCa. Recall and comprehension of germline genetic testing results, uptake of post-test clinical recommendations, and psychological impact of germline genetic testing among patients with PCa were evaluated. METHODS: This is a secondary analysis of data from the PROCLAIM trial. PROs were analyzed overall and by germline genetic testing results. Differences between groups were determined by two-tailed Fisher's exact test with significance set at p < 0.05. RESULTS: Among 494 patients with informative survey responses, 60% and 71% accurately recalled and interpreted their germline genetic testing results, respectively, with the highest rates among patients with negative results and the lowest among those with variant of uncertain significance-only (VUS) results. Among 42/55 (76%) patients with positive results for whom clinicians made germline genetic testing-informed recommendations, 39 (93%) completed or planned to complete >1 clinical recommendation. Conversely, no further recommendations were made for 160/221 (72%) and 211/218 (97%) patients with VUS and negative results, respectively. However, 57% (213/371) of these patients indicated that they or their family members intended to pursue clinical management strategies that were not recommended by their clinicians. Of the patients who responded to the survey, >90% of patients reported no post-germline genetic testing increase in their level of concern for themselves or their family members. CONCLUSION: germline genetic testing for patients with PCa did not cause appreciable psychological harm to the tested patients. Furthermore, patients with positive results had a high uptake of clinician-recommended management strategies. Of note, there were inconsistencies in the understanding of VUS results, with some clinicians making recommendations not warranted by personal/family history; conversely, some patients pursued management strategies not recommended by their clinicians. This suggests that educational efforts are needed in the communication of germline genetic testing results and clinical recommendations to patients.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Shore ND, Pieczonka CM, Heron S, et al. Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients. Prostate Cancer Prostatic Dis. 2025. PMID: 40983675. doi:10.1038/s41391-025-01013-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。